» COVID-19 Information


Manage your account, request prescriptions, set up appointments & more.

Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label



Clinical Trial Title

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

Trial Status

Closed to Enrollment

Start Date

November 1, 2018

Trial Type

Cancer - Adult Oncology

Specific Condition

Endometrial Cancer


This phase II trial studies how well olaparib and cediranib maleate work in treating patients with endometrial cancer that has come back, does not respond to treatment, or has spread to other places in the body. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility Criteria

Eligibility Criteria

  • Patients must have recurrent or persistent endometrial carcinoma, which is refractory to curative therapy or established treatments.
  • Patients must have measurable disease as defined by RECIST 1.1 or non-measurable (detectable) disease.
  • Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma.
  • Patients may have received non cytotoxic therapy including immunotherapy but excluding cediranib and olaparib for management of recurrent or persistent disease.
  • Patients must have an ECOG Performance Status of 0, 1 or 2 (Karnofsky ≥ 60%) within 7 days prior to registration

Please contact Legacy Oncology Research for additional study inclusion/exclusion information. 




IRB Number

Central IRB

Principal Investigator Name

Colleen McCormick, MD

Contact Name

Oncology Clinical Research



Contact Fax


Contact E-Mail


Last Updated: Tuesday, October 5, 2021 03:33:39 PM